Immunoprecise Antibodies Ltd
NASDAQ:IPA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.329
3.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cash Flow Statement
Cash Flow Statement
Immunoprecise Antibodies Ltd
| Jan-2022 | ||
|---|---|---|
| Operating Cash Flow | ||
| Net Income |
(19)
|
|
| Depreciation & Amortization |
7
|
|
| Change in Deffered Taxes |
1
|
|
| Other Non-Cash Items |
6
|
|
| Cash Taxes Paid |
2
|
|
| Cash Interest Paid |
0
|
|
| Change in Working Capital |
(2)
|
|
| Cash from Operating Activities |
(9)
N/A
|
|
| Investing Cash Flow | ||
| Capital Expenditures |
(2)
|
|
| Other Items |
(1)
|
|
| Cash from Investing Activities |
(4)
N/A
|
|
| Financing Cash Flow | ||
| Net Issuance of Common Stock |
45
|
|
| Net Issuance of Debt |
(1)
|
|
| Cash from Financing Activities |
43
N/A
|
|
| Change in Cash | ||
| Effect of Foreign Exchange Rates |
(1)
|
|
| Net Change in Cash |
30
N/A
|
|
| Free Cash Flow | ||
| Free Cash Flow |
(11)
N/A
|
|
